P-182 Developing a VR intervention that will help people living with advanced cancer to manage pain

Résumé fourni par la source

Background Many people living with advanced cancer experience pain, which is often poorly controlled (Greco, Roberto, Corli, et al. J Clin Oncol. 2014;32(36):4149-54). Virtual Reality is a non-drug alternative that could help manage pain (Austin, Siddall, Lovell. Support Care Cancer. 2022;30(5):3995-4005). VR has rapidly developed over the last 20 years and has haphazardly been implemented across hospices, with limited guidance on where and when to use it. Aim To develop a VR intervention that will help people living with advanced cancer to manage pain. Methods The study has four locations in the UK and three phases: Qualitative interviews with 40 people who are living with advanced cancer and experiencing pain (Jan 2025 – May 2025). During this they will complete a VR experience. They will provide data about their diagnosis and pain. They will give feedback on the technology. Online focus groups with up to 10 staff at each location (June 2025 – Sept 2025) to identify local barriers and facilitators to using VR. Implementation phase with 20 people who are living with advanced cancer (Oct 2025 – Nov 2025). We will develop a manual of use from the data to describe how and where a VR intervention might work. Results We are currently finishing phase 1. To date, 32 people have participated in an interview. The analysis is yet to start, but we will present key findings from these interviews; particularly what the participants enjoyed about the technology, what they would change, and where/when/how they would use the technology alongside their routine care. We will report data from phase 2 and what key barriers and facilitators were identified by staff. Conclusion This is the first study to develop a VR intervention to help people living with advanced cancer to manage their pain. The manual will help provide guidance and clarity to those seeking to implement VR in their own practice. Research Funder NIHR Research for Patient Benefit (NIHR206696).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.